Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine

Neuroendocrinology Letters

Volumn 28, Issue 1, 2007, Pages 59-64

  Waberžinek, Gerhard ^a,d   Marková, Jolana ^b   Mastík, Jiří ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Acute migraine attack; Intravenous sodium valproate; Migraine prophylaxis; Visual analogue scale (VAS)

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; CINNARIZINE; CLONAZEPAM; DILTIAZEM; ERGOTAMINE; GABAPENTIN; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROIC ACID;

ACUTE DISEASE; ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE REACTION; INTERVIEW; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; PAIN ASSESSMENT; PROPHYLAXIS; RELAPSE; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 33847127347     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine. A double-blind study versus placebo. Cephalalgia. 1992; 12: 81-84.
2. Raskin NH. Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale. Neurology. 1993; 43: 3942.
3. Jensen R. et al. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology. 1994; 44: 647-651
4. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995; 52: 281-286.
5. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia. 1997; 17: 81-83
6. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einhäupl KM, Arnold G. Valproic acid is effective in migraine prophylaxis at low serum levels: A prospective open-label study. Headache. 2001; 41: 774-778
7. Mathew NT, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (Depacon) aborts migraine rapidly: a preliminary report. Headache. 2000; 40: 720-723.
8. Norton J. Use of intravenous valproate sodium in status migraine. Headache. 2000; 40: 755-757.
9. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001; 41: 976-980
10. Krusz JC. Intravenous valproate sodium in the treatment of migraine headaches in the headache clinic. Headache. 2001; 12: 39-41
11. Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache. 2004; 44: 65-69.
12. Headache classification committee of the IHS. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8: 1-96.
13. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999; 19: 107-114.